 Home > Active Ingredient News > Antitumor Therapy > J Gastroenterol: Residual HBV DNA and pgRNA in patients with chronic hepatitis B can increase the risk of liver cancer by 2-5 times!

J Gastroenterol: Residual HBV DNA and pgRNA in patients with chronic hepatitis B can increase the risk of liver cancer by 2-5 times!

 Last Update: 2021-04-13
 Source: Internet
 Author: User

Tags

1 3 5 trimethylbenzene

natural vitamin serum

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Hepatitis B virus (HBV) is an important risk factor for patients with chronic hepatitis B (CHB) to develop hepatocellular carcinoma (HCC).

In 2016, there were approximately 880,000 HBV-related HCC deaths worldwide

In the past 20 years, the use of effective nucleotide analogs (ie reverse transcriptase inhibitors [NRTI]) has significantly changed the course of CHB.

This study aims to evaluate whether residual HBV viremia after NRTI treatment is related to the occurrence of HCC.

104 cases of patients treated with Entecavir (ETV) for at least 3 years, and Cobas Taqman method V2.

diagnosis

Detection of HBV DNA at the time of diagnosis of HCC

Among these 104 patients (male 80.

Serum DNA was not detected in 38.

Detection of HBV pgRNA at the time of diagnosis of HCC

It can be detected that HBV DNA and pgRNA are associated with the 2-year increased risk of HCC (hazard ratio [HR] 2.

It can be detected that HBV DNA and pgRNA are associated with an increased 2-year risk of HCC (hazard ratio [HR] is 2.

In patients with CHB standard method for detecting HBV DNA in below the LLOQ, detected by a more sensitive method, there is a continuing viremia found in up to 50% of patients related to HBV DNA or the occurrence of HCC pgRNA HBV DNA Or pgRNA is related to the occurrence of HCC

Original source:

Mak Lung-Yi,Huang Qi,Wong Danny Ka-Ho et al.

org/10.
1007/s00535-021-01780-5" target="_blank" rel="noopener">Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.